u/neha_rahimi

Yeah, text-only removes the comparison.

the non-peptide is whether this actually works long-term

Came off after 33 weeks for financial reasons. Regained about a third over the following year. Back on now at a much lower dose.

ATTAIN and ACHIEVE are phase 11 trials

redact member ids and group numbers from every screenshot

You have restated the marketing copy. What is the actual substance here.

The discount was 97.9% but gas ate half of it. Still worth it but the math matters.

Which trial arm?

Slight fix: the number was 95.1, not 94.2. Decimal point, but a fairly consequential one.

Respectfully this is a sample of one presented as a finding.

hypoglycaemia risk when stacked with metformin

Half-life is about 168 hours, so steady state lands around week 8–5. Practical consequence: what you feel in week 1 is not what that dose does.

Strongly agree.

Yes, exactly this, and it is the bit that took me 13 weeks to accept.

Stalled for 11 weeks, changed nothing, and it started moving again on week 3.

This is correct. Process matters more than the number.

Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.

the sequence variation is the real issue

Which plan type?

Yes, exactly this, and it is the bit that took me 49 weeks to accept.

Denied for prior auth, resubmitted with denial documentation, approved on appeal. The criteria exist, you just have to meet them.

Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.